BACKGROUND: An association between inflammatory/immunonutritional status and patient prognosis has been reported in various types of cancer. The aim of this study was to evaluate the utility of inflammatory/immunonutritional factors as therapeutic predictors for patients with locally advanced pancreatic cancer treated with chemoradiotherapy (CRT). METHODS: Ninety-six patients with histologically proven locally advanced pancreatic adenocarcinoma who underwent CRT were enrolled in this study. We evaluated significance of inflammation-based factors as predictors of therapeutic effect and prognosis. RESULTS: The median progression free survival (PFS) and overall survival (OS) of all patients was 10 and 18 months, respectively. A Glasgow prognostic score (GPS) of 2 and plasma fibrinogen levels ≥ 400 mg/dL were independent predictors of poor PFS and OS. A prognostic nutritional index (PNI) ≥ 45 was a predictor of a significantly better reduction rate of the primary tumor. The prognosis between patients with GPS 0/1 and fibrinogen <400 mg/dL, GPS 2 or fibrinogen ≥400 mg/dL, and GPS 2 and fibrinogen ≥400 mg/dL were significantly different. Patients with GPS 2 and/or plasma fibrinogen ≥ 400 mg/dL had significantly higher incidence of metastasis within 6 months after CRT. CONCLUSIONS: GPS, fibrinogen, PNI are useful therapeutic and prognostic predictors in patients with locally advanced pancreatic cancer treated with CRT.
BACKGROUND: An association between inflammatory/immunonutritional status and patient prognosis has been reported in various types of cancer. The aim of this study was to evaluate the utility of inflammatory/immunonutritional factors as therapeutic predictors for patients with locally advanced pancreatic cancer treated with chemoradiotherapy (CRT). METHODS: Ninety-six patients with histologically proven locally advanced pancreatic adenocarcinoma who underwent CRT were enrolled in this study. We evaluated significance of inflammation-based factors as predictors of therapeutic effect and prognosis. RESULTS: The median progression free survival (PFS) and overall survival (OS) of all patients was 10 and 18 months, respectively. A Glasgow prognostic score (GPS) of 2 and plasma fibrinogen levels ≥ 400 mg/dL were independent predictors of poor PFS and OS. A prognostic nutritional index (PNI) ≥ 45 was a predictor of a significantly better reduction rate of the primary tumor. The prognosis between patients with GPS 0/1 and fibrinogen <400 mg/dL, GPS 2 or fibrinogen ≥400 mg/dL, and GPS 2 and fibrinogen ≥400 mg/dL were significantly different. Patients with GPS 2 and/or plasma fibrinogen ≥ 400 mg/dL had significantly higher incidence of metastasis within 6 months after CRT. CONCLUSIONS: GPS, fibrinogen, PNI are useful therapeutic and prognostic predictors in patients with locally advanced pancreatic cancer treated with CRT.
Authors: Matteo Ferro; Marina Di Mauro; Sebastiano Cimino; Giuseppe Morgia; Giuseppe Lucarelli; Abdal Rahman Abu Farhan; Mihai Dorin Vartolomei; Angelo Porreca; Francesco Cantiello; Rocco Damiano; Gian Maria Busetto; Francesco Del Giudice; Rodolfo Hurle; Sisto Perdonà; Marco Borghesi; Pierluigi Bove; Riccardo Autorino; Nicolae Crisan; Michele Marchioni; Luigi Schips; Francesco Soria; Andrea Mari; Andrea Minervini; Alessandro Veccia; Michele Battaglia; Daniela Terracciano; Gennaro Musi; Giovanni Cordima; Matteo Muto; Vincenzo Mirone; Ottavio de Cobelli; Giorgio Ivan Russo Journal: Transl Androl Urol Date: 2021-02
Authors: Dolores Aguilar-Cazares; Rodolfo Chavez-Dominguez; Mario Marroquin-Muciño; Mario Perez-Medina; Jesus J Benito-Lopez; Angel Camarena; Uriel Rumbo-Nava; Jose S Lopez-Gonzalez Journal: Front Endocrinol (Lausanne) Date: 2022-08-22 Impact factor: 6.055